Latest Regulatory Decisions News

Atlas Arteria extinguishes a US$100 million put option with Ontario Teachers’ Pension Plan, pauses Chicago Skyway sale, and faces a dismissed Dulles Greenway rate case with potential appeal.

The Takeovers Panel has declined Humm Group’s request to swap its independent board committee chair, citing concerns over undisclosed conflicts and procedural missteps.

Imricor Medical Systems has submitted the third of four Premarket Approval modules to the FDA, marking a key step towards US approval of its MR-guided cardiac ablation devices.

The Takeovers Panel has declined to investigate Skin Elements Limited's allegations of undisclosed investor associations following a $2.5 million placement, after 62 Capital agreed to waive transfer restrictions on placement securities.

Bremworth Limited reiterates confidence in its Floorscape acquisition scheme despite ongoing regulatory uncertainty, signalling readiness to explore alternatives if the New Zealand Commerce Commission declines clearance.

The Takeovers Panel has declined to find unacceptable circumstances in Diamond Infraco’s bid for Atlas Arteria, accepting ASIC relief and an undertaking that address concerns over the conditional price increase mechanism.

The Takeovers Panel has declined Atlas Arteria’s bid to block Diamond Infraco from dispatching its takeover Bidder’s Statement, prolonging uncertainty over the contested offer.

Clarity Pharmaceuticals has secured a major manufacturing deal with Nucleus RadioPharma to produce its next-generation prostate cancer imaging agent, 64Cu-SAR-bisPSMA, ramping up supply ahead of anticipated US market entry.

Manuka Resources’ subsidiary Trans-Tasman Resources has received a draft decision proposing to decline consent for its Taranaki VTM iron sands project, challenging the company’s plans to develop a critical minerals supply in New Zealand.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Pancontinental Energy has identified two new prospects in its PEL 87 permit, boosting its high case prospective resources to 6.1 billion barrels of oil net to the company. While progressing farmout discussions, the company awaits a critical permit extension decision from Namibian authorities.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.